Nicholas V Nguyen1,2,3, Jane Gralla4,5, James Abbott6, Anna L Bruckner4,7. 1. Division of Dermatology, Akron Children's Hospital, Akron, OH, USA. 2. Department of Internal Medicine, Northeast Ohio Medical University, Rootstown, OH, USA. 3. Department of Pediatrics, Northeast Ohio Medical University, Rootstown, OH, USA. 4. Department of Pediatrics, School of Medicine, University of Colorado, Aurora, CO, USA. 5. Department of Biostatistics and Informatics, School of Medicine, University of Colorado, Aurora, CO, USA. 6. College of Medicine, Drexel University, Philadelphia, PA, USA. 7. Department of Dermatology, School of Medicine, University of Colorado, Aurora, CO, USA.
Abstract
BACKGROUND/ OBJECTIVES: There are no reliably effective, well-tolerated topical agents for the treatment of hyperhidrosis. We sought to evaluate the efficacy and tolerability of oxybutynin 3% gel in adolescents and young adults with primary focal hyperhidrosis. METHODS:Patients with severe axillary hyperhidrosis were treated with topical oxybutynin 3% gel for 4 weeks. Response to treatment was assessed by calculating change in Hyperhidrosis Disease Severity Score from baseline to weeks 1 and 4. Change in health-related quality of life was assessed using the Children's Dermatology Life Quality Index or the Dermatology Life Quality Index. Adverse effects were evaluated using patient diaries, investigator global review, and physical examination. RESULTS: Of 10 patients aged 13-24 enrolled, seven completed the study. Of those who completed the study, four (57.1%) reported reduction in axillary Hyperhidrosis Disease Severity Score at week 1 and all seven (100%) at week 4. Six patients (85.7%) reported reduction in Children's Dermatology Life Quality Index or Dermatology Life Quality Index score. Anticholinergic adverse effects were infrequent. The majority of treatment-related adverse events were mild to moderate in severity. One patient experienced a severe adverse event. CONCLUSION: Oxybutynin 3% gel reduced hyperhidrosis severity and improved health-related quality of life in this small pilot study. Safety and efficacy should be further evaluated in a large, prospective, placebo-controlled study.
RCT Entities:
BACKGROUND/ OBJECTIVES: There are no reliably effective, well-tolerated topical agents for the treatment of hyperhidrosis. We sought to evaluate the efficacy and tolerability of oxybutynin 3% gel in adolescents and young adults with primary focal hyperhidrosis. METHODS:Patients with severe axillary hyperhidrosis were treated with topical oxybutynin 3% gel for 4 weeks. Response to treatment was assessed by calculating change in Hyperhidrosis Disease Severity Score from baseline to weeks 1 and 4. Change in health-related quality of life was assessed using the Children's Dermatology Life Quality Index or the Dermatology Life Quality Index. Adverse effects were evaluated using patient diaries, investigator global review, and physical examination. RESULTS: Of 10 patients aged 13-24 enrolled, seven completed the study. Of those who completed the study, four (57.1%) reported reduction in axillary Hyperhidrosis Disease Severity Score at week 1 and all seven (100%) at week 4. Six patients (85.7%) reported reduction in Children's Dermatology Life Quality Index or Dermatology Life Quality Index score. Anticholinergic adverse effects were infrequent. The majority of treatment-related adverse events were mild to moderate in severity. One patient experienced a severe adverse event. CONCLUSION:Oxybutynin 3% gel reduced hyperhidrosis severity and improved health-related quality of life in this small pilot study. Safety and efficacy should be further evaluated in a large, prospective, placebo-controlled study.
Authors: Amy S Paller; Puja R Shah; Amanda M Silverio; Annette Wagner; Sarah L Chamlin; Anthony J Mancini Journal: J Am Acad Dermatol Date: 2012-03-07 Impact factor: 11.527
Authors: Nelson Wolosker; Claudio Schvartsman; Mariana Krutman; Taiz Pereira Dozono Almeida Campbell; Paulo Kauffman; Jose Ribas M de Campos; Pedro Puech-Leão Journal: Pediatr Dermatol Date: 2013-04-29 Impact factor: 1.588
Authors: Adelaide A Hebert; Dee Anna Glaser; Lawrence Green; William P Werschler; Douglass W Forsha; Janice Drew; Ramanan Gopalan; David M Pariser Journal: Pediatr Dermatol Date: 2018-11-19 Impact factor: 1.588